Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8LAE2
|
|||
| Drug Name |
Sacituzumab govitecan
|
|||
| Synonyms |
hRS7-SN38; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; UNII-M9BYU8XDQ6; hRS 7SN38; Satralizumab linker; IMMU 132; IMMU-132; M9BYU8XDQ6; 1491917-83-9; sacituzumab-govitecan; DA64T2C2IO; CYSTEINYL CL2A-SN-38; SN-38 CYSTEINYL CONJUGATE; DTXSID401335985; EX-A4354; GOVITECAN CYSTEINYL CONJUGATE; F82944; 1535963-91-7; 1796566-95-4
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Approved | [1] | |
| Urothelial carcinoma [ICD-11: 2C92.0] | Approved | [1] | ||
| Non-small-cell lung cancer [ICD-11: 2C25] | Phase 3 | [2] | ||
| Company |
Gilead
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C76H104N12O24S
|
|||
| Canonical SMILES |
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O
|
|||
| InChI |
InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1
|
|||
| InChIKey |
ULRUOUDIQPERIJ-PQURJYPBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tumor associated calcium signal transducer 2 (TACSTD2) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. | |||
| REF 2 | ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health. | |||
| REF 3 | Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.